Outset Medical, Inc. — Q3 2022 Form 10-Q Summary
Business Context and Reporting Period
Outset Medical develops and sells the Tablo Hemodialysis System, an FDA-cleared dialysis platform designed for hospital, clinic, and home use. The filing covers the three and nine months ended September 30, 2022; results are unaudited.
In late July 2022, the FDA cleared the Company’s 510(k) application for patient use of Tablo in the home. Outset resumed marketing and shipping for home use after implementing a shipment hold in May 2022.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Total revenue | $27.8 million | $26.3 million | $83.4 million | $74.5 million |
| Gross profit | $4.3 million | $2.9 million | $12.6 million | $4.3 million |
| Gross margin | 15.6% | 11.2% | 15.1% | 5.8% |
| Loss from operations | $(41.0) million | $(30.1) million | $(121.2) million | $(89.7) million |
| Net loss | $(40.8) million | $(30.5) million | $(121.5) million | $(90.7) million |
| Net loss per share | $(0.85) | $(0.65) | $(2.54) | $(1.96) |
| Cash flow from operations | Not separately provided | Not separately provided | $(111.2) million | $(97.6) million |
Q3 revenue increased 5%, while nine-month revenue increased 12%. Product revenue was $21.7 million in Q3 and $67.0 million for nine months. Service and other revenue was $6.0 million in Q3 and $16.3 million for nine months.
As of September 30, 2022, cash and cash equivalents were $63.9 million, short-term investments were $163.6 million, and restricted cash was $33.3 million. Total cash, cash equivalents, short-term investments, and restricted cash were $260.8 million. Inventories increased to $55.3 million from $39.2 million at December 31, 2021.
Debt consisted of a $30.0 million SVB term loan, reported net of discount at $29.8 million. The loan was repaid in November 2022 in connection with new SLR credit facilities.
Material Changes Versus the Prior Comparable Period
- Q3 revenue increased $1.4 million, or 5%; nine-month revenue increased $8.9 million, or 12%.
- Q3 product revenue was essentially flat, as a $0.5 million decline in console revenue was largely offset by a $0.4 million increase in consumables revenue. Nine-month product revenue increased 10%, primarily due to higher consumables revenue.
- Service and other revenue increased 34% in Q3 and 19% for the nine-month period, primarily reflecting the larger installed console base.
- Gross margin improved by 4.4 percentage points in Q3 and 9.3 percentage points for the nine-month period, driven by cost-reduction activities, console pricing, and product mix. Freight and materials costs continued to pressure consumables margins.
- Operating expenses increased 37% in Q3 and 42% for nine months. Nine-month research and development, sales and marketing, and general and administrative expenses increased 48%, 56%, and 15%, respectively.
- Q3 net loss increased $10.3 million, and nine-month net loss increased $30.8 million, reflecting substantially higher operating expenses despite improved gross profit.
- Stock-based compensation increased to $7.4 million in Q3 and $19.9 million for the nine-month period, compared with $2.9 million and $12.7 million, respectively, in the prior-year periods.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide a clear numerical revenue, margin, or earnings guidance range. Management expects significant expenses and operating losses to continue while investing in commercial infrastructure, product development, and growth.
- Customer staffing shortages, inflation, tighter hospital budgets, and increased scrutiny of capital purchases lengthened sales cycles, delayed installations, and adversely affected bookings and revenue in the second and third quarters.
- The home-use shipment hold negatively affected Q2 and Q3 bookings, revenue, and the home patient pipeline. Management expects recovery to take time and stated that related disruptions may continue.
- Supply-chain constraints, freight costs, material costs, and potential disruptions involving contract manufacturers and critical suppliers could adversely affect product availability, margins, and results.
- On November 3, 2022, Outset entered senior secured SLR credit facilities providing for up to $300.0 million of aggregate borrowing capacity. The Term A facility funded $100.0 million; additional borrowing is subject to revenue milestones, borrowing-base limitations, and lender approval.
- The SLR facilities bear variable interest tied to one-month term SOFR and are secured by substantially all Company assets, including intellectual property. They include restrictive covenants and a financial covenant beginning with the quarter ending December 31, 2023.
- The Company repaid the SVB term loan using SLR proceeds, including a $0.3 million early repayment fee and a $2.0 million final payment.
- A purported stockholder securities class action filed in July 2022 was voluntarily dismissed without prejudice in September 2022 and is concluded.
Management stated that existing cash, investments, cash generated from sales, and available proceeds from the new debt financing should be sufficient to meet anticipated needs for at least the next 12 months from the filing date. The Company nevertheless has a history of recurring losses and negative operating cash flow.
Important Facts for Investors to Verify
- Whether home-market bookings, shipments, and patient adoption recovered after the July 2022 FDA clearance.
- Whether staffing shortages, hospital budget pressure, and longer sales cycles continue to constrain revenue growth.
- Progress toward sustained gross-margin improvement, particularly given freight and material-cost inflation.
- Cash-burn trends relative to the $260.8 million liquidity balance reported at September 30, 2022.
- Actual borrowings, interest expense, collateral requirements, and covenant compliance under the SLR facilities.
- Whether the Company can achieve the revenue milestones required to access the additional SLR borrowing capacity.
- The impact of continued operating losses, inventory growth, stock-based compensation, and any need for additional capital.